Spero therapeutics, inc. (SPRO)
CashFlow / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Cash flows from operating activities:
Net loss

-23,258

-24,986

-17,717

-13,150

-5,072

-10,599

-10,463

-9,956

-10,644

-13,868

-9,844

-9,763

-6,411

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

189

-111

489

188

184

139

81

94

95

99

94

83

87

Non-cash lease cost

110

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of derivative liabilities

-

-

-

-

-

-

-

-

-

3,088

2

-350

-1,199

Share-based compensation

1,110

929

981

933

933

769

705

661

614

373

931

61

62

Realized (gain) loss on investments

-

0

0

0

1

-

-

-

-

-

-

-

-

Unrealized foreign currency transaction (gain) loss

-453

182

-193

-66

95

-136

19

-248

-8

-

-

-

-

Accretion of discount on marketable securities

53

87

102

206

355

325

234

67

45

-

-

-

-

Changes in operating assets and liabilities:
Other receivables

-5,036

2,747

2,940

1,617

80

44

-462

-425

208

474

309

114

-190

Prepaid expenses and other current assets

860

1,148

-2,612

-1,638

448

6,203

-109

7

-604

779

101

-174

-131

Tax incentive receivables

233

-618

84

173

62

210

-1,408

383

45

1,005

186

461

159

Other assets

1,224

2,480

-313

1,178

-433

-

-

-

-

-

-

-

-

Accounts payable

4,824

1,605

1,485

482

-3,008

2,172

659

-278

-2,469

2,461

-230

200

-82

Accrued expenses and other current liabilities

-9,379

10,861

5,147

966

-3,364

1,203

1,562

645

165

304

-748

1,325

434

Deferred rent

-

-

-

-

-

645

-32

-23

-36

-33

-33

435

-497

Other long-term liabilities

-44

-8

-36

-19

11

-

-

-

-

-

-

-

-

Advance payments from collaborator

-

-

-

-

-

-

-

-

-

-

-

-

465

Net cash used in operating activities

-23,329

-17,367

-9,659

-12,070

-10,924

-13,509

-5,514

-8,641

-11,961

-

-

-

-

Cash flows from investing activities:
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-6,979

Purchases of marketable securities

3,995

12,470

43,670

7,018

25,835

25,754

81,596

0

22,825

-

-

-

-

Proceeds from maturities of marketable securities

31,850

8,500

27,800

31,950

50,587

-

-

-

-

-

-

-

-

Purchases of property and equipment

79

129

17

87

81

-

-

-

-

-

-

-

-

Net cash provided by (used in) investing activities

27,776

-4,099

-15,887

24,845

24,671

7,287

-72,618

5,000

-22,825

-

-

-

-

Cash flows from financing activities:
Proceeds from equity offering

-

5,501

38

8,726

1,525

-

-

-

-

-

-

-

-

Payment of offering costs

352

-

79

63

16

-

-

-

-

-

-

-

-

Proceeds from stock option exercises

539

98

51

300

59

-

-

-

-

-

-

-

-

Net cash provided by financing activities

30,186

5,599

10

8,963

1,568

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

34,633

-15,867

-25,536

21,738

15,315

-6,400

-8,235

-3,837

-34,786

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

43,001

Net increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

36,022

Supplemental disclosure of non-cash investing and financing activities:
Purchases of property and equipment included in accounts payable and accrued expenses

-

-

-

-

75

-

-

-

-

-

-

-

-

Offering costs in accounts payable and accruals

109

-

-

-

-

-

-

-

-

-

-

-

-

Conversion of bridge units into preferred units

-

-

-

-

-

-

-

-

-

0

0

0

8,500

Settlement of derivative liabilities upon issuance of preferred units

-

-

-

-

-

-

-

-

-

0

0

0

944

Cumulative dividends on redeemable convertible preferred shares

-

-

-

-

-

-

-

-

-

-

-

-

1,236

Accretion of redeemable convertible preferred units to redemption value

-

-

-

-

-

-

-

-

-

-

-

-

18

Accretion of bridge units to redemption value

-

-

-

-

-

-

-

-

-

0

0

0

576

Rights Offering [Member]
Proceeds from equity offering

9,416

-

-

-

-

-

-

-

-

-

-

-

-

Series C Preferred Stock [Member]
Proceeds from issuance of Series C Preferred Shares

20,583

-

-

-

-

-

-

-

-

-

-

-

-

Payment of offering costs

41

-

-

-

-

-

-

-

-

-

-

-

-

Series C issuance costs in accounts payable

41

-

-

-

-

-

-

-

-

-

-

-

-